Bliss Gvs Pharma Ltd vs Ind Swift Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 276.25 as of 30 Apr 15:30 . The P/E Ratio of Bliss GVS Pharma Ltd changed from 14.9 on March 2021 to 14.7 on March 2025 . This represents a CAGR of -0.27% over 5 yearsThe P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 2.3 on March 2025 . This represents a CAGR of -30.66% over 3 years The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1018 crore on March 2021 to ₹ 1238 crore on March 2025 . This represents a CAGR of 4.00% over 5 yearsThe Market Cap of Ind-Swift Laboratories Ltd changed from ₹ 425.72 crore on March 2021 to ₹ 509.08 crore on March 2025 . This represents a CAGR of 3.64% over 5 years The revenue of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 236.71 crore as compare to the Sep '25 revenue of ₹ 252.86 crore. This represent the decline of -6.39% The revenue of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 178.43 crore as compare to the Sep '25 revenue of ₹ 170.5 crore. This represent the growth of 4.65% The ebitda of Bliss GVS Pharma Ltd for the Dec '25 is ₹ 50.73 crore as compare to the Sep '25 ebitda of ₹ 51.94 crore. This represent the decline of -2.33% The ebitda of Ind-Swift Laboratories Ltd for the Dec '25 is ₹ 25.9 crore as compare to the Sep '25 ebitda of ₹ 19.34 crore. This represent the growth of 33.92% The net profit of Bliss GVS Pharma Ltd changed from ₹ 22.11 crore to ₹ 24.78 crore over 7 quarters. This represents a CAGR of 6.73% The net profit of Ind-Swift Laboratories Ltd changed from ₹ 1.01 crore to ₹ 9.52 crore over 7 quarters. This represents a CAGR of 260.37% The Dividend Payout of Bliss GVS Pharma Ltd changed from 7.64 % on March 2021 to 7.64 % on March 2025 . This represents a CAGR of 0.00% over 5 yearsThe Dividend Payout of Ind-Swift Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bliss GVS Pharma Ltd

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company has its manufacturing facility at Palghar which is WHO GMP approved.
The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards. The company commenced its business in 1985.
In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

About Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, Punjab, India.
The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

FAQs for the comparison of Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Ind-Swift Laboratories Ltd?

Market cap of Bliss GVS Pharma Ltd is 2,922 Cr while Market cap of Ind-Swift Laboratories Ltd is 1,190 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd?

The stock performance of Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd?

As of May 4, 2026, the Bliss GVS Pharma Ltd stock price is INR ₹276.25. On the other hand, Ind-Swift Laboratories Ltd stock price is INR ₹137.15.

How do dividend payouts of Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Ind-Swift Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.